尊敬的各位嘉宾、各位投资者： 大家好！ 欢迎大家参加深圳北芯生命科技股份有限公司首次公开发行股票并在科创板上市的网上投资者交流会。 我谨代表北芯生命，向长期以来关注、支持北芯生命的投资者、合作伙伴以及各界朋友表示热烈的欢迎 和衷心的感谢！ 北芯生命自成立以来，始终秉持"用创新和品质改善生命健康"的使命，致力于开发为心血管疾病诊疗带 来变革的精准介入解决方案。前不久，北芯生命刚度过十周年生日，站在了全新的起点上。从扎根中国 的创新萌芽，到成长为中国高性能医疗器械出海的新生代领军力量，我们始终以临床和患者为中心，坚 持产品创新与极致品质，目前已经围绕冠状动脉疾病、外周血管疾病、房颤等领域建立了核心研发技术 平台，并推出了一系列自主研发的心血管智能化精准介入解决方案。 北芯和北芯人，通过满腔热情和日夜兼程，已填补中国医疗器械产业领域中技术壁垒最高、产业链条最 长的高性能心血管精准介入器械板块的空白。此次在科创板上市，通过上市募集资金，公司将进一步加 大在创新研发和产业化上的投入，进一步丰富在研产品管线数量和扩大产能。通过持续不断地做出有临 床价值的技术突破和创新产品，我们将继续为海内外患者和临床工作者提供更精准、更 ...

作为北芯生命此次发行上市的保荐人和主承销商，中金公司在与公司长期合作进程中，既见证了公司稳 健快速的发展，亦深切体会到公司管理层超前的行业洞察力与深厚的从业经验。公司的技术平台、研发 体系以及丰富的产品管线，都为未来的长期发展奠定了坚实基础。此次上市，将为公司注入更多的资本 力量，进一步推动其核心产品的产业化进程，加强全球市场布局，并推动公司向世界级医疗科技企业的 目标迈进。 我们相信，通过此次公开发行，北芯生命能够充分释放其创新潜力。我们也期待，北芯生命这样一家优 秀的医疗器械企业，在资本市场的大舞台上，展现更加亮眼的成绩。 在今天的网上交流中，我们将认真负责地回答各位投资者朋友提出的问题，让大家能更全面、深入地了 解北芯生命，帮助大家把握投资机会，共享北芯生命的发展硕果。欢迎大家踊跃提问，积极申购。 最后，预祝北芯生命本次发行圆满成功！谢谢大家！ 尊敬的各位嘉宾、各位投资者朋友： 大家好！ 首先，我谨代表中国国际金融股份有限公司，向所有参与深圳北芯生命科技股份有限公司网上投资者交 流会的嘉宾和投资者表示热烈的欢迎和衷心的感谢！ 北芯生命自成立以来，凭借强大的自主研发能力、技术创新积累和良好的市场口碑，迅速 ...

北芯生命：专注心血管精准介入领域用创新和品质改善生命健康 ——深圳北芯生命科技股份有限公司首次公开发行股票并在科创板上市网上投资者交流会精彩回放 出席嘉宾 深圳北芯生命科技股份有限公司董事长、总经理（首席执行官）宋亮先生 深圳北芯生命科技股份有限公司董事、副总经理、财务负责人（首席财务官）连菲女士 深圳北芯生命科技股份有限公司董事会秘书罗睿先生 罗睿：公司是一家专注于心血管疾病精准诊疗创新医疗器械研发、生产和销售的国家高新技术企业，致 力于开发为心血管疾病诊疗带来变革的精准解决方案。自成立以来，公司根据心血管疾病诊疗临床需求 和前沿技术发展持续布局了冠状动脉疾病、外周血管疾病及房颤等领域。 问：公司的主要产品和服务有哪些？ 罗睿：截至2025年9月30日，公司累计向市场推出11个产品，在研产品共有6个，覆盖IVUS系统、FFR 系统、血管通路产品、冲击波球囊治疗系统及电生理解决方案五大产品类别。公司核心产品包括血管内 超声（IVUS）诊断系统和血流储备分数（FFR）测量系统。 问：请介绍公司主要业务的经营情况。 罗睿：公司核心产品FFR系统于2020年上市后，即于2021年占据了30.6%的国内市场份额。截至 ...

Core Insights - The 2025 Future Medical and Pharmaceutical Top 100 Exhibition (VBEF) was held in Suzhou, showcasing advancements in medical technology, with Shenzhen Beixin Life Technology Co., Ltd. recognized in the "Top 100 Chinese Innovative Medical Devices and Intelligent Manufacturing" list [1] - Beixin Life's core product, the Intravascular Ultrasound (IVUS) system, won the "Best Intelligent Medical Device Technology Innovation Product" award, marking a significant achievement in the cardiovascular precision intervention field [1][2] - The company has successfully broken the long-standing dominance of imported products in China's cardiovascular precision diagnosis market, completing this transition in nine years [1] Product and Technology Highlights - The IVUS system features a 60MHz imaging resolution, high retraction speed, and intelligent operation, establishing a strong position in the domestic market [2] - It is the first domestically developed IVUS system approved under the EU MDR, successfully entering international markets [2] - The FFR (Fractional Flow Reserve) system, another core product, is recognized as the first domestically approved gold standard FFR system, showcasing Beixin Life's technological leadership [2] Innovation and Development - Beixin Life has established four core technology platforms: micro-nano device research and packaging, interventional catheter research and processes, high-performance medical hardware development, and high-performance signal and image algorithms [2][3] - The company has launched 11 commercialized products based on these platforms, obtaining over 20 Class III medical device registration certificates, and serving more than 1,000 hospitals and 150,000 patients globally [2] - The IVUS system incorporates advanced features such as the inSmartVision platform for automatic image analysis and the EasyGO function for angiography registration, enhancing clinical efficiency and reducing procedure time [3] Future Aspirations - Beixin Life aims to continue its mission of improving life and health through innovation and quality, aspiring to become a world-class medical technology enterprise with lasting influence [3] - The recognition from the awards and the inclusion in the top 100 list serve as validation of the company's technological innovations and clinical value, motivating further advancements in the cardiovascular precision intervention sector [3]

Core Insights - The National Medical Products Administration of China emphasizes support for high-end medical device innovation, particularly in advanced medical imaging equipment, to address the growing global demand for cardiovascular disease treatment solutions [1] - Beixin Life, a domestic company focused on high-end medical device innovation, aims to develop high-performance interventional medical devices to tackle the significant public health issue of cardiovascular diseases [1][3] - The company has successfully developed and commercialized proprietary high-performance diagnostic equipment, contributing to the advancement of domestic high-end medical devices [1][3] Industry Overview - Coronary heart disease is recognized as a major health threat globally, with cardiovascular diseases being the leading cause of death in China [2] - China has the highest annual volume of percutaneous coronary intervention (PCI) procedures, with a trend towards precision treatment guided by advanced coronary functional and imaging technologies [2] - The reliance on imported devices and materials has historically dominated the market due to high R&D barriers and long return cycles [2] Company Achievements - Since its establishment in 2015, Beixin Life has developed a series of intelligent cardiovascular interventional solutions, including the first domestically approved IVUS and FFR systems [3][4] - The company has obtained over 20 Class III medical device registrations and successfully launched 11 products [3] - Beixin Life is the only domestic company with the technology to develop and manufacture 60MHz high-frequency micro-ultrasound transducers and MEMS pressure sensor modules [4] Market Potential - The cardiovascular device market is the second largest globally and is expected to grow rapidly over the next decade, with a significant patient population for coronary heart disease [7] - The number of PCI procedures in China is projected to increase from 1.906 million in 2024 to 4.298 million by 2030, with a compound annual growth rate of approximately 14.5% [7] - The precision PCI market in China is expected to grow from 2.04 billion yuan in 2022 to 9.42 billion yuan by 2030, with a compound annual growth rate exceeding 20% [7] Competitive Position - Beixin Life's FFR product captured 30.6% of the domestic market share shortly after its launch, while its IVUS product became the leading domestic option, reducing reliance on imports [8] - The company has successfully expanded its products to international markets, receiving positive feedback and achieving routine clinical use in multiple countries [8] - Beixin Life aims to enhance the synergy of its product system and adapt to international markets, thereby improving the global competitiveness of China's high-performance medical device industry [9]

Core Insights - North Chip Life Technology Co., Ltd. has focused on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases since its establishment in 2015 [1] - The company has broken the monopoly of overseas giants in the field of cardiovascular precision intervention and has filled multiple domestic gaps [1] - North Chip Life has received over ten Class III medical device registration certificates both domestically and internationally, with 185 authorized patents as of June 30, 2025, including 86 invention patents [1] Product Highlights - The company's intravascular ultrasound (IVUS) system is the first domestically approved high-definition (60 MHz) IVUS product in China and the first to be approved for overseas sales (EU MDR) [1] - The core product, the fractional flow reserve (FFR) measurement system, is also the first domestically approved FFR product in China and the first to be approved for overseas sales (EU MDR), recognized as "internationally leading and domestically pioneering" by the National Medical Products Administration [1] - These products have significantly improved the precision and effectiveness of cardiovascular disease diagnosis and treatment [2] Market Reach and Recognition - North Chip Life's cardiovascular precision intervention solutions have been implemented in over 1,500 hospitals across more than 50 countries, benefiting over 150,000 patients globally [2] - The FFR system has been recognized by Boston Consulting Group as a representative product of China's medical device innovation 3.0 [2] - The 2024 Medical Device Industry Innovation Index recognized North Chip Life as one of the "Top 100 Innovative Enterprises" and "Outstanding Enterprises in Overseas Expansion" [2] Future Vision - The company aims to become a world-class medical technology enterprise with a lasting impact, continuing to invest in research and development to provide more quality diagnostic options for global cardiovascular disease patients [3]

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. is a leading domestic innovator in the cardiovascular medical device sector, focusing on increasing the localization rate of high-end medical equipment and addressing the growing global demand for cardiovascular disease treatment solutions [1][3]. Financial Performance - In 2024, Beixin's revenue reached 316.60 million yuan, marking a year-on-year growth of over 70% compared to 2023's 183.98 million yuan [2]. - The company has achieved positive cash flow from operating activities, with significant losses narrowing and approaching breakeven [2]. - Sales expense ratio and management expense ratio decreased by approximately 21 percentage points and 26 percentage points, respectively, indicating improved operational efficiency [2]. Market Position and Product Development - Beixin has solidified its position as a leader in the domestic cardiovascular precision interventional device market, with its IVUS system becoming the first domestically produced product to receive EU MDR certification and achieve sales of over 217 million yuan in 2024 [3]. - The FFR system, as the first approved gold standard FFR product in China, has been adopted in approximately 1,000 hospitals nationwide since its launch in 2020 [3]. - The company has launched 11 products to date, with 6 more in development, covering various innovative fields related to coronary artery disease, peripheral vascular disease, and atrial fibrillation treatment [4]. Research and Development - Beixin has increased its R&D investment and was recognized as a national "specialized, refined, and innovative" small giant enterprise in July 2023 [4]. - The company is set to introduce a new generation of integrated functional imaging solutions and the first domestic all-crown functional evaluation solution by 2025 [4]. - Beixin's pulse field ablation technology has entered the special review process for innovative medical devices, with clinical trials selected for the 2025 European Society of Cardiology Congress [4]. International Expansion - In 2024, Beixin achieved overseas revenue of 38.83 million yuan, a nearly 160% increase compared to 2023 [5]. - The company aims to transition from "high-end substitution" to "global leadership" in the cardiovascular precision intervention field, with a vision to become a world-class medical technology enterprise [5].

Core Viewpoint - North Chip Life Technology Co., Ltd. is preparing for its IPO on the Sci-Tech Innovation Board, focusing on innovative medical devices in the cardiovascular precision intervention field [1] Company Overview - Established in 2015, North Chip Life specializes in high-performance active interventional devices for major diseases such as coronary heart disease and atrial fibrillation [1] - The company has developed key technologies, including the first domestically developed FFR system and a 60MHz high-speed IVUS system, breaking foreign monopolies [1] - Over ten products have been commercialized, with FFR and IVUS systems used in approximately 1,000 hospitals globally [1] Research and Development - North Chip Life has significantly increased R&D investment, establishing four technical platforms covering the entire chain from core sensor packaging to image analysis algorithms [1] - The company has applied for over 360 patents, with more than 180 granted, including over 80 invention patents and 14 PCT international patent applications [2] Financial Performance - Revenue figures for 2022, 2023, and 2024 are approximately 0.92 billion, 1.84 billion, and 3.17 billion respectively, with positive operating cash flow and narrowing losses [2] - Sales and management expense ratios are projected to decrease by about 21 percentage points and 26 percentage points respectively in 2024, indicating improved operational efficiency [2] Market Potential - The number of PCI procedures in China reached 1.636 million in 2023, expected to grow to 4.3 million by 2030, driving demand for the company's core products [3] - The precision PCI market in China is projected to grow from 2.04 billion in 2022 to 9.42 billion by 2030, with a compound annual growth rate exceeding 20% [3] Global Expansion - North Chip Life is the first domestic company to obtain EU CE/MDR certification for both FFR and IVUS products, with regular supply to countries like Germany, the UK, and Italy [2] - In 2024, overseas revenue reached approximately 38.83 million, a year-on-year increase of nearly 160% [2] Vision and Future Plans - The company aims to become a world-class medical technology enterprise with a long-lasting impact, focusing on technology accumulation, product matrix, and global layout [3] - With a solid R&D capability and high-performance product matrix, North Chip Life is positioned to become a representative enterprise in the high-end medical device sector in China [3]